Enalapril(CAS:75847-73-3)

Enalapril, CAS 75847-73-3, is a second-generation long-acting angiotensin-converting enzyme inhibitor (ACEI) and a classic and essential API in global cardiovascular treatment. Compared with the first-generation captopril, Enalapril has been greatly improved in efficacy duration, stability and safety. With stable long-term antihypertensive performance, reliable target organ protection and low adverse reaction rate, it has become a basic raw material for standardized treatment of hypertension and heart failure, widely used in pharmaceutical mass production and new drug research. Featuring stable chemical properties, high purity and strict impurity control, Enalapril fully meets international pharmacopoeia standards and is suitable for manufacturing oral tablets and other mainstream pharmaceutical dosage forms.

In terms of pharmacological mechanism, Enalapril is a prodrug that is hydrolyzed into active enalaprilat after entering the human body. It specifically inhibits angiotensin-converting enzyme and blocks the conversion of angiotensin I to angiotensin II. As a powerful vasoconstrictor, angiotensin II causes vascular contraction, elevated blood pressure, water-sodium retention and myocardial fibrosis. By cutting off this pathological pathway, Enalapril effectively dilates peripheral blood vessels, reduces vascular resistance and stabilizes blood pressure. Meanwhile, it inhibits aldosterone secretion, reduces water and sodium retention, relieves cardiac load, reverses ventricular hypertrophy and vascular remodeling, and realizes long-term protection of the heart, kidneys and blood vessels, significantly reducing the risk of cardiovascular events.

Clinically, Enalapril has wide indications and stable curative effects, serving as a first-line API for hypertension and heart failure treatment. For primary and secondary hypertension, its 24-hour long-acting effect ensures stable blood pressure control and avoids sharp day-night blood pressure fluctuations, suitable for long-term maintenance treatment of mild, moderate and severe hypertension. For patients with chronic congestive heart failure and left ventricular dysfunction, Enalapril improves myocardial blood supply, reduces cardiac preload and afterload, enhances exercise tolerance and delays disease progression, effectively lowering hospitalization and mortality rates. In addition, it can be flexibly combined with diuretics and calcium channel blockers to achieve synergistic effects, making it an indispensable component of compound antihypertensive preparations.

In terms of safety and industrial application, Enalapril presents excellent overall tolerance. Compared with short-acting ACEIs, it has a significantly lower incidence of dry cough and fewer side effects such as tachycardia and orthostatic hypotension, enabling safe long-term medication for elderly and chronic disease patients. It has no obvious liver and kidney toxicity under conventional doses with mild metabolism. At present, Enalapril adopts mature synthetic processes with stable batch quality, high purity and low impurities, fully supporting large-scale standardized production. With the comprehensive advantages of long-lasting efficacy, high safety and multi-target organ protection, Enalapril remains one of the most mainstream cardiovascular APIs in the global pharmaceutical market, maintaining stable market demand and broad development prospects in chronic disease prevention and treatment.